Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 65, Issue 10, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00936-21
Keywords
beta-lactamases; enzyme kinetics; mechanisms of resistance; metalloenzymes
Categories
Funding
- NHMRC [APP1084778]
Ask authors/readers for more resources
The study investigates a fourth variant of metallo-beta-lactamase, SIE-1, which shows higher activity towards cephalosporins. The unusual preference of SIE-1 for cephalosporins and its presence in a widespread environmental organism suggest the potential for increased MBL-mediated beta-lactam resistance. Including SIE-1 in MBL inhibitor design studies could expand the therapeutic scope of much needed antiresistance drugs.
The structural diversity in metallo-beta-lactamases (MBLs), especially in the vicinity of the active site, has been a major hurdle in the development of clinically effective inhibitors. Representatives from three variants of the B3 MBL subclass, containing either the canonical HHH/DHH active-site motif (present in the majority of MBLs in this subclass) or the QHH/DHH (B3-Q) or HRH/DQK (B3-RQK) variations, were reported previously. Here, we describe the structure and kinetic properties of the first example (SIE-1) of a fourth variant containing the EHH/DHH active-site motif (B3-E). SIE-1 was identified in the hexachlorocyclohexane-degrading bacterium Sphingobium indicum, and kinetic analyses demonstrate that although it is active against a wide range of antibiotics, its efficiency is lower than that of other B3 MBLs but has increased efficiency toward cephalosporins relative to other beta-lactam sub-strates. The overall fold of SIE-1 is characteristic of the MBLs; the notable variation is observed in the Zn1 site due to the replacement of the canonical His116 by a glutamate. The unusual preference of SIE-1 for cephalosporins and its occurrence in a widespread environmental organism suggest the scope for increased MBL-mediated b- lactam resistance. Thus, it is relevant to include SIE-1 in MBL inhibitor design studies to widen the therapeutic scope of much needed antiresistance drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available